Refractory Anemia With Excess Blasts in Transformation Completed Phase 2 Trials for Thalidomide (DB01041)

Also known as: Refractory anemia with excess blasts in transformation / Acute myeloblastic leukemia, minimal differentiation / Refractory anaemia with excess blasts in transformation / Myelodysplastic syndrome transformation

IndicationStatusPhase
DBCOND0028567 (Refractory Anemia With Excess Blasts in Transformation)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00015990Thalidomide in Treating Patients With Myelodysplastic SyndromeTreatment